top of page

NCI-2017-01380

OPTIMICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients who Achieve PCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy


This research study is investigating a drug called MK-3475 (pembrolizumab) for triple-negative breast cancer (TNBC). Pembrolizumab is a drug that helps the immune system fight cancer cells. The study is designed to see how pembrolizumab affects the tumor microenvironment, which is the area around the tumor that contains cells and substances. Pembrolizumab is given before surgery (pre-operative) with or without intra-operative Radiation Therapy (IORT). Researchers hope to learn if pembrolizumab can alter the tumor microenvironment in a way that makes the cancer more susceptible to treatment.


Triple-Negative: It is a type of breast cancer in which cells do not have estrogen receptors (ER), progesterone receptors (PR), and HER-2 receptors.

Intra-operative Radiation Therapy (IORT): Intraoperative radiation therapy (IORT) is a kind of radiation treatment that is performed during surgery. Radiation therapy (also called radiotherapy) is a cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumors. This radiotherapy is a newer method that aims the radiation beam directly on the tissue with cancer.


For more information about the trial, click the link below:

NCI-2017-01380

Clinical Trial Site: Columbia


To see all available clinical trials click here.



Recent Posts

See All

NCI-2019-07694

Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract Cancer (NAPOLI-2) This is a research study called NAPOLI-2. It is designed to see

NCT05908786

A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED PLATFORM STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT IMMUNOTHERAPY COMBINATIONS IN PATIENTS WITH SURGICALLY RESECTABLE HEPATOCELLULAR CAR

NCT05904886

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatoce

Comments


bottom of page